Authors: Eskens, FALM Greim, GA van Zuylen, C Wolff, I Denis, LJ Planting, AST Muskiet, FA Wanders, J Barbet, NC Choi, L Capdeville, R Verweij, J Hanauske, AR Bruntsch, U

Citation: Falm. Eskens et al., Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors, CLIN CANC R, 6(5), 2000, pp. 1736-1743

Authors: Kappauf, H Leykauf-Ammon, D Bruntsch, U Horneber, M Kaiser, G Buschel, G Gallmeier, WM

Citation: H. Kappauf et al., Use of and attitudes held towards unconventional medicine by patients in adepartment of internal medicine oncology and haematology, SUPP CARE C, 8(4), 2000, pp. 314-322

Authors: Zhou, HH Choi, L Lau, H Bruntsch, U De Vries, EEGE Eckhardt, G Van Oosterom, AT Verweij, J Schran, H Barbet, N Linnartz, R Capdeville, R

Citation: Hh. Zhou et al., Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486Ain phase I studies in patients with advanced cancers, J CLIN PHAR, 40(3), 2000, pp. 275-283

Authors: Tesch, H Diehl, V Lathan, B Hasenclever, D Sieber, M Ruffer, U Engert, A Franklin, J Pfreundschuh, M Schalk, KP Schwieder, G Wulf, G Dolken, G Worst, P Koch, P Schmitz, N Bruntsch, U Tirier, C Muller, U Loeffler, M

Citation: H. Tesch et al., Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's Lymphoma Study Group, BLOOD, 92(12), 1998, pp. 4560-4567